Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,734 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,061 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04367805 | COVID-19 Infection in Patients With Hepatocellular Carcinoma(COVID19-CHIEF) | active not recruiting | — | 23 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05358249 | Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation(KontRASt-03) | active not recruiting | Phase 1 / Phase 2 | 74 | Novartis PharmaceuticalsINDUSTRY |
| 8 |
| Jun 15, 2026 |
| clinicaltrials |
| NCT07646717 | Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma(LPHAIC for ICC) | active not recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT03104439 | Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer | active not recruiting | Phase 2 | 84 | Massachusetts General HospitalOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04560712 | Acupuncture for the Management of Postoperative Pain in Patients With Pancreatic or Colorectal Cancer Undergoing Surgery | active not recruiting | N/A | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04616183 | LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04729322 | Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders | active not recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05075993 | Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors | active not recruiting | Phase 1 | 352 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05384444 | Effect of FMD on Colorectal Cancer Patients(FCRC22) | active not recruiting | N/A | 602 | Fudan UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06109467 | Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer | active not recruiting | Phase 2 | 8 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07645209 | A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold Regions | active not recruiting | — | 1,000 | Harbin Medical UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04017650 | Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 38 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04658147 | Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) | active not recruiting | Phase 1 | 31 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06204159 | Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery(Trinav) | active not recruiting | N/A | 12 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04587128 | Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC | active not recruiting | Phase 2 | 34 | University of Wisconsin, MadisonOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05827055 | Proglumide and Chemotherapy for Metastatic Pancreatic Cancer(ProGem) | active not recruiting | Phase 2 | 30 | Georgetown UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06900543 | Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere(CHEERS) | active not recruiting | Phase 3 | 108 | Chengdu New Radiomedicine Technology Co. LTD.INDUSTRY | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07369219 | The Impact of AI-Assisted Nursing Care Intervention Within the Enhanced Recovery Framework on Outcomes of Colorectal Surgery Patients | active not recruiting | N/A | 70 | Bahçeşehir UniversityOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07466225 | HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion | active not recruiting | — | 150 | Peking UniversityOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07635290 | Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer | active not recruiting | Phase 2 | 26 | West China HospitalOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT05245786 | An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer | active not recruiting | Early Phase 1 | 14 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05789069 | A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 83 | HiFiBiO TherapeuticsINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT04832763 | Medical and Psychosocial Issues in Adolescents and Young Adults With Colorectal Cancer | active not recruiting | N/A | 32 | University of Southern CaliforniaOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06643715 | Research of the Application of Pancreatic Cancer Screening Artificial Intelligence Model "PANDAPro" | active not recruiting | N/A | 100,000 | Zhejiang UniversityOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT03132922 | MAGE-A4ᶜ¹º³²T for Multi-Tumor | active not recruiting | Phase 1 | 71 | USWM CT, LLCINDUSTRY | 2 | Jun 4, 2026 | clinicaltrials |
| NCT03781323 | Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer | active not recruiting | Phase 2 | 12 | University of RochesterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07619859 | Impact of Fusobacterium Nucleatum on Response to Anti-EGFR Therapy in Metastatic Colorectal Cancer | active not recruiting | — | 500 | Barretos Cancer HospitalOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT00492999 | Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver | active not recruiting | Phase 2 | 64 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04753879 | Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. | active not recruiting | Phase 2 | 38 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07076121 | A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) | active not recruiting | Phase 2 / Phase 3 | 470 | Bristol-Myers SquibbINDUSTRY | 36 | Jun 3, 2026 | clinicaltrials |
| NCT07444905 | Prospective Evaluation of a Locked Risk-Stratified Surveillance Strategy for Extrahepatic Metastasis in Hepatocellular Carcinoma | active not recruiting | — | 1,523 | Tongji HospitalOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07622693 | Beta-Blockers on Neoadjuvant Immunochemotherapy for Hypertensive Patients With Gastric Cancer(BNIHGC) | active not recruiting | — | 80 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT02379377 | 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant | active not recruiting | Phase 1 | 110 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04513418 | Effects of Preoperative Enteral Immunonutrition for Esophageal Cancer Patients Given Neoadjuvant Chemoradiotherapy(POINT) | active not recruiting | Phase 3 | 244 | Hecheng Li M.D., Ph.DOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05007015 | Transanal Irrigation for the Management of LARS(TAI-LARS) | active not recruiting | N/A | 66 | Jewish General HospitalOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05056077 | Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)(TTBF) | active not recruiting | N/A | 353 | University of California, San FranciscoOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06625320 | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)(RASolute 302) | active not recruiting | Phase 3 | 500 | Revolution Medicines, Inc.INDUSTRY | 7 | Jun 2, 2026 | clinicaltrials |
| NCT02451982 | Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas | active not recruiting | Phase 2 | 76 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03257761 | Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer | active not recruiting | Phase 1 | 55 | University of Southern CaliforniaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03801083 | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers | active not recruiting | Phase 2 | 4 | Udai KammulaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03935893 | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers | active not recruiting | Phase 2 | 20 | Udai KammulaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05507632 | Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma | active not recruiting | Phase 2 | 48 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05720910 | Streamlined Geriatric and Oncological Evaluation Based On IC Technology(FRONE) | active not recruiting | N/A | 720 | Institut BergoniéOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05783622 | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | active not recruiting | Phase 1 | 130 | Janux TherapeuticsINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06360354 | A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)(MTAPESTRY 103) | active not recruiting | Phase 1 | 120 | AmgenINDUSTRY | 16 | Jun 1, 2026 | clinicaltrials |
| NCT02757859 | WASH Trial: Intraoperative Lavage as a Treatment for Pancreatic Cancer | active not recruiting | N/A | 845 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04956640 | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | active not recruiting | Phase 1 / Phase 2 | 540 | Eli Lilly and CompanyINDUSTRY | 6 | May 29, 2026 | clinicaltrials |
| NCT06465563 | SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer | active not recruiting | Phase 2 | 93 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT07613125 | The Effect of Locally Made Nutritional Supplementation on Cancer Cachexia in Bangladesh: A Quasi-experimental Study. | active not recruiting | N/A | 106 | International Centre for Diarrhoeal Disease Research, BangladeshOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT02403505 | Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer(CEA+RC-BCG) | active not recruiting | Phase 1 | 20 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jun 15, 2026source: clinicaltrials